trending Market Intelligence /marketintelligence/en/news-insights/trending/bcKvReE-t3SisMuT-I4Myg2 content esgSubNav
In This List

Adaptimmune, Bellicum to collaborate on T-cell therapies

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Adaptimmune, Bellicum to collaborate on T-cell therapies

Adaptimmune Therapeutics PLC and Bellicum Pharmaceuticals Inc. signed a deal to collaborate on the evaluation, development and commercialization of next-generation T-cell therapies.

The companies said they agreed to utilize Adaptimmune's affinity-optimized SPEAR T-cells to evaluate Bellicum's GoTCR technology for the potential to create enhanced T-cell receptor product candidates. Based on the results of the pre-clinical proof-of-concept phase, the companies will move to a two-target co-development and co-commercialization phase.